AbbVie abandons late-stage lung cancer asset Rova-T [Reuters (UK)]
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations: investors.abbvie.com/investor-overview
AbbVie abandons late-stage lung cancer asset Rova-T - Reuters 2 Min Read (Reuters) - AbbVie Inc said on Thursday it will cease to develop its experimental drug Rova-T after the treatment failed to show survival benefit in a late-stage trial for a type of lung cancer. The drugmaker acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, but recorded impairment charges of about $4 billion in January after it halted enrolment of a separate study testing the therapy. An independent data monitoring committee recommended terminating the trial after an interim data analysis, the company said on Thursday. Rova-T is a drug-antibody combination that targets a protein called DLL3, found in over 80% of patients with small-cell lung cancer. AbbVie, which is testing treatments for more than 20 different types of cancer, said it will now prioritize other development programs within its cancer pipeline. The drugmaker in June said it would acquire Allergan Plc for about $63 billion
[Read more]
| Impact snapshot | Event time: | ABBV | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ABBV alerts
ABBV alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- U.S. FDA declines to approve Revance's frown-line treatment [Financial Post (Toronto, Ontario, Canada)]Financial Post
- U.S. FDA declines to approve Revance's frown-line treatment [Reuters]Reuters
- AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)PR Newswire
- Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer AwarenessPR Newswire
- AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial SpondyloarthritisPR Newswire
- More
ABBV
SEC Filings
- 10/4/21 - Form 4
- 10/4/21 - Form 4
- 10/4/21 - Form 4
- ABBV's page on the SEC website
- More